The impact of 21-Gene Recurrence Score test and classic clinical-pathologic factors in guiding adjuvant therapy for HER-2 negative, ER-positive, early-stage breast cancer: A retrospective study

Breast J. 2020 May;26(5):1064-1066. doi: 10.1111/tbj.13787. Epub 2020 Mar 3.
No abstract available

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Chemotherapy, Adjuvant
  • Humans
  • Neoplasm Recurrence, Local* / genetics
  • Neoplasm Recurrence, Local* / pathology
  • Neoplasm Staging
  • Receptor, ErbB-2 / genetics
  • Receptors, Estrogen
  • Retrospective Studies

Substances

  • Receptors, Estrogen
  • Receptor, ErbB-2